Whole-Genome Shotgun Assembly and Analysis of the Genome

Total Page:16

File Type:pdf, Size:1020Kb

Whole-Genome Shotgun Assembly and Analysis of the Genome R ESEARCH A RTICLE of the human genome, it contains a comparable complement of protein-coding genes, as in- Whole-Genome Shotgun ferred from random genomic sampling (3). Subsequently, more-targeted analyses (5–9) Assembly and Analysis of the showed that the Fugu genome has remarkable homologies to the human sequence. The intron- Genome of Fugu rubripes exon structure of most genes is preserved be- tween Fugu and human, in some cases with Samuel Aparicio,2,1* Jarrod Chapman,3 Elia Stupka,1* conserved alternative splicing (10). The relative Nik Putnam,3 Jer-ming Chia,1 Paramvir Dehal,3 compactness of the Fugu genome is accounted Alan Christoffels,1 Sam Rash,3 Shawn Hoon,1 Arian Smit,4 for by the proportional reduction in the size of introns and intergenic regions, in part owing to Maarten D. Sollewijn Gelpke,3 Jared Roach,4 Tania Oh,1 3 1 3 1 the relative scarcity of repeated sequences like Isaac Y. Ho, Marie Wong, Chris Detter, Frans Verhoef, those that litter the human genome. Conserva- 3 1 3 3 Paul Predki, Alice Tay, Susan Lucas, Paul Richardson, tion of synteny was discovered between hu- Sarah F. Smith,5 Melody S. Clark,5 Yvonne J. K. Edwards,5 mans and Fugu (5, 6), suggesting the possibil- Norman Doggett,6 Andrey Zharkikh,7 Sean V. Tavtigian,7 ity of identifying chromosomal elements from Dmitry Pruss,7 Mary Barnstead,8 Cheryl Evans,8 Holly Baden,8 the common ancestor. Noncoding sequence Justin Powell,9 Gustavo Glusman,4 Lee Rowen,4 Leroy Hood,4 comparisons detected core conserved regulato- ry elements in mice (11). This methodology has Y. H. Tan,1 Greg Elgar,5* Trevor Hawkins,3*† 1 3 1,10 subsequently been used for identifying con- Byrappa Venkatesh, * Daniel Rokhsar, * Sydney Brenner * served elements in several other loci (12–24). These remarkable homologies, conserved over The compact genome of Fugu rubripes has been sequenced to over 95% the 450 million years since the last common coverage, and more than 80% of the assembly is in multigene-sized scaffolds. ancestor of humans and teleost fish, combined In this 365-megabase vertebrate genome, repetitive DNA accounts for less than with the compact nature of the Fugu sequence, one-sixth of the sequence, and gene loci occupy about one-third of the genome. led to the formation of the Fugu Genome Con- As with the human genome, gene loci are not evenly distributed, but are sortium to sequence the pufferfish genome. clustered into sparse and dense regions. Some “giant” genes were observed that had average coding sequence sizes but were spread over genomic lengths Whole-Genome Shotgun Sequencing significantly larger than those of their human orthologs. Although three-quar- and Assembly of the Fugu rubripes ters of predicted human proteins have a strong match to Fugu, approximately Genome a quarter of the human proteins had highly diverged from or had no pufferfish Sequencing and assembly. Shotgun libraries homologs, highlighting the extent of protein evolution in the 450 million years were prepared from genomic DNA that had since teleosts and mammals diverged. Conserved linkages between Fugu and been purified from the testis of a single animal human genes indicate the preservation of chromosomal segments from the to minimize complications due to allelic poly- common vertebrate ancestor, but with considerable scrambling of gene order. morphisms. These polymorphisms are estimat- ed to occur at 0.4% of the nucleotides in our Introduction sons between the genomes of different animals individual fish, ϳfourfold as many as in human Most of the genetic information that governs will guide future approaches to understanding (25). We set out to generate ϳ6ϫ genome how humans develop and function is encoded gene function and regulation. A decade ago, coverage of the Fugu genome (Table 1). Sev- in the human genome sequence (1, 2), but our analysis of the compact genome of the puffer- eral plasmid libraries with 2- and 5.5-kb understanding of the sequence is limited by our fish Fugu rubripes was proposed (3) as a cost- inserts were constructed and end-sequenced ability to retrieve meaning from it. Compari- effective way to illuminate the human sequence by dye terminator and dye primer chemis- through comparative analysis within the verte- tries. The bulk of the sequence coverage brates. We report here the sequencing and ini- resulted from 2-kb libraries (Table 1). 1Institute of Molecular and Cell Biology, 30 Medical Drive, Singapore 117609. 2University of Cambridge, tial analysis of the Fugu genome, the first pub- However, the 5.5-kb library provided cru- Department of Oncology, Hutchison–MRC Research licly available draft vertebrate genome to be cial intermediate-range linking information Centre, Cambridge CB22XZ,UK. 3U.S. DoE Joint published after the human genome. By compar- for assembly. Genome Institute, 2800 Mitchell Drive, Walnut Creek, ison with mammalian genomes the task was Reads passing the primary quality and CA 94598, USA. 4Institute for Systems Biology, 1441 North 34th Street, Seattle, WA 98103, USA. 5MRC UK modest, since almost an order of magnitude less vector screens (“passing reads”) were assem- HGMP Resource Centre, Hinxton, Cambridge CB10 effort is needed to obtain a comparable amount bled into scaffolds by means of JAZZ, a 1SB, UK. 6Los Alamos National Laboratory, Los of information. modular suite of tools for large shotgun as- Alamos, NM 87545, USA. 7Myriad Genetics Inc., 320 Fugu rubripes, commonly known as “tora- semblies that incorporates both read-overlap Wakara Way, Salt Lake City, UT 84108, USA. 8Celera Genomics, 45 West Gude Drive, Rockville, MD 20850, fugu,” is a teleost fish belonging to the Order and read-pairing information USA. 9Paradigm Therapeutics Ltd., Physiological Lab- Tetraodontiformes and Family Tetraodontidae. The 3.71 million passing reads were assem- oratory, Cambridge CB23EG, UK. 10Salk Institute, Its natural habitat spans the Sea of Japan, the bled into 12,381 scaffolds longer than 2 kb, for 10010 North Torrey Pines Road, La Jolla, San Diego, East China Sea, and the Yellow Sea. Early a total of 332.5 Mb. The scaffolding range and CA 92037–1099, USA. work (4) suggested that Tetraodontiformes contiguity of the assembly are shown in table *To whom correspondence and requests for materials should be addressed. E-mail: [email protected] have low nuclear DNA content [less than 500 S1. A total of 745 scaffolds longer than 100 kb (S.A.), [email protected] (E.S.), [email protected] million base pairs (Mb) per haploid genome], account for 35% of the assembled sequence (G.E.), [email protected] which led to the conjecture that the genomes of (119.5 Mb); 1908 scaffolds longer than 50 kb (T.H.), [email protected] (B.V.), dsrokhsar@lbl. these creatures were compact in organization. account for 60% of the assembly (200.8 Mb); gov (D.R.), [email protected] (S.B.). †Present address: Amersham Biosciences, 928 East Although the Fugu genome is unusually small 4108 scaffolds longer than 20 kb account for Arques Avenue, Sunnyvale, CA 945085, USA. for a vertebrate, at about one-eighth the length 81% of the assembly (271 Mb). www.sciencemag.org SCIENCE VOL 297 23 AUGUST 2002 1301 R ESEARCH A RTICLE These scaffolds contain 45,024 contigs that of the remaining four have 6- to 8.5-kb pieces shotgun assembly by a 500-bp inversion at one total 322.5 Mb of assembled sequence. The missing from the scaffolds in regions that are end of the BAC. Small cloning inversions have remaining 10 Mb of scaffold sequence consists clearly repetitive, on the basis of their depth of been noted on BAC and cosmid clone ends in of 32,621 “captured” or “sequence-mapped” high-quality coverage. The fourth (GenBank ac- previous studies and may explain this discrep- gaps (i.e., gaps flanked by contigs that are cession number AH007668) contains the T cell ancy. The JAZZ assembly at this location is connected by spanning clones). These gaps receptor (TCR)–␣ locus and was matched in the supported by strong paired-end linking informa- were up to 4 kb in length, with an average size assembly only within the coding sequence of the tion; raw sequence data for the BAC itself were of 306 base pairs (bp). These gaps are indicated V region, suggesting a cloning or assembly unavailable. As the BAC and shotgun sequences in the scaffold sequence by runs of N’s whose problem. Similarly, all exons of a well-annotat- are from different individual fish, this is a pos- length is the best estimate of gap size on the ed set of 209 Fugu genes from GenBank could sible polymorphism (25). Unlike the human ge- basis of the spanning clones; by convention, be located within the assembly, with the excep- nome, there is no chromosomal or genetic in- gaps projected to be shorter than 50 bp are tion of two odorant receptor genes that were formation on gene loci that requires integration, indicated by 50 N’s. Gaps account for Ͻ3% of found in the unassembled reads. The single- nor in this present assembly was a physical the total scaffold length. exon odorant receptor genes are often found in clone map integrated with the genome sequence. Five percent of the passing reads were with- tandem arrays separated by repetitive sequence, The scaffolds are therefore not mapped onto held from assembly as being from high percent which may account for their absence in the Fugu chromosomes. nucleotide identity, high–copy number repeats current assembly. (25). About 20% of these reads have sisters The accuracy of the sequence was measured Preliminary Annotation and Analysis placed in the assembly and therefore should by comparing the assembly consensus with the of the Fugu Genome contribute to filling in some captured gaps; this finished sequence of cosmid 165K09 (Gen- We annotated the scaffolds with putative gene gap closing is ongoing.
Recommended publications
  • 28Th Course in Medical Genetics
    European School of Genetic Medicine th 28 Course in Medical Genetics Bertinoro University Residential Centre Via Frangipane, 6 – Bertinoro Course Directors: H. Brunner (Nijmegen, The Netherlands), G.Romeo (Bologna, Italy), B.Wirth (Cologne, Germany) 1 28th Course in Medical Genetics CONTENTS PROGRAMME 3 ABSTRACTS OF LECTURES 7 ABSTRACTS OF STUDENTS POSTERS 37 STUDENTS WHO IS WHO 40 FACULTY WHO IS WHO 51 2 Arrival: Saturday May 16 Sunday, May 17 Morning Session: Introduction to Human Genome Analysis 8.30 – 9.00 Registration to the course 9.00 – 9.30 Introduction to the course G. Romeo 9.30 – 10.15 Medical Genetics Today D. Donnai 10.15 – 11.00 Genotypes & phenotypes H. Brunner 11.00 – 11.30 Coffee Break 11.30 – 12.15 Introduction in Next Generation Sequencing technologies and applications J. Veltman 12.15 – 13.00 How to deal with next generation sequencing output. C. Gilissen 13.10 – 14.00 Lunch Break Afternoon Session: 14.30 – 16.00 Concurrent Workshops 16.00-16.30 Coffee Break 16.30 – 18.00 Concurrent Workshops 3 Monday, May 18 Morning Session: Approaches to Clinical and Molecular Genetics 9.00 – 9.50 Linkage and association (in a conceptual and historic perspective) A. Read 9.50- 10.40 Arrays and CNVs E. Klopocki 10.40 – 11.10 Coffee Break 11.10 – 12.00 Molecular syndromology in the NGS-era: which phenotype, which family, which strategy? Applications to aging research B. Wollnik 12.00 – 12.50 Bottlenecks in understanding mitochondrial diseases P. Chinnery 13.10 – 14.00 Lunch Break Afternoon Session: 14.30 – 16.00 Concurrent Workshops – including Ethics by Andrew Read 16.00-16.30 Coffee Break 16.30 – 18.00 Concurrent Workshops 18.30 – 19.30 Poster Viewing Session 4 Tuesday, May 19 Morning Session: Gene regulation and complex genetic disorders 9.00 - 9.50 Preventing and treating mitochondrial diseases Patrick Chinnery 9.50 – 10.40 Epigenetics and disease K.
    [Show full text]
  • A Rare Variant in D-Amino Acid Oxidase Implicates NMDA Receptor Signaling and Cerebellar Gene Networks in Risk for Bipolar Disorder
    medRxiv preprint doi: https://doi.org/10.1101/2021.06.02.21258261; this version posted June 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Submitted Manuscript: Confidential Template updated: February 2021 Title: A rare variant in D-amino acid oxidase implicates NMDA receptor signaling and cerebellar gene networks in risk for bipolar disorder Authors: Naushaba Hasin (1), Lace M. Riggs (2,3), Tatyana Shekhtman (4), Justin Ashworth (5), Robert Lease (1,6), Rediet T. Oshone (1), Elizabeth M. Humphries (1,7), Judith A. Badner (8), Pippa A. Thompson (9), David C. Glahn (10), David W. Craig (11), Howard J. Edenberg (12), Elliot S. Gershon (13), Francis J. McMahon (14), John I. Nurnberger (15), Peter P. Zandi (16), John R. Kelsoe (4), Jared C. Roach (5), Todd D. Gould (3,17,18), and Seth A. Ament* (1,3) Affiliations: 1. Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA 2. Program in Neuroscience, University of Maryland School of Medicine, Baltimore, MD, USA 3. Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA 4. Department of Psychiatry, University of California San Diego, La Jolla, CA, USA 5. Institute for Systems Biology, Seattle, WA, USA 6. Program in Molecular Medicine, University of Maryland School of Medicine, Baltimore, MD, USA 7. Program in Molecular Epidemiology, University of Maryland School of Medicine, Baltimore, MD, USA 8.
    [Show full text]
  • GWG Dec 2012 Nominee Bios2
    Agenda Item #12 ICOC Meeting December 12, 2012 CIRM Scientific and Medical Research Funding Working Group Biographical information of candidates nominated to serve as Scientific Members of the Working Group Stephen Friend, MD, PhD Dr. Friend is the President of Sage Bionetworks. He received his BA in philosophy, his PhD in biochemistry, and his MD from Indiana University. He is an authority in the field of cancer biology and a leader in efforts to make large scale, data-intensive biology broadly accessible to the entire research community. Dr. Friend has been a senior advisor to the National Cancer Institute (NCI), several biotech companies, a Trustee of the American Association for Cancer Research (AACR), and is an American Association for the Advancement of Science (AAAS) and Ashoka Fellow as well as an editorial board member of Open Network Biology. Dr. Friend was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck’s Basic Cancer Research efforts. Prior to joining Merck, Dr. Friend was recruited by Dr. Leland Hartwell to join the Fred Hutchinson Cancer Research Center’s Seattle Project, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 2001. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. Christie Gunter, PhD Dr. Gunter is the HudsonAlpha director of research affairs. She earned her BS degree in both genetics and biochemistry from the University of Georgia in 1992, and a PhD in genetics from Emory University in 1998.
    [Show full text]
  • Final Program
    © Istock FINAL PROGRAM SUMMARY Organizing & Scientifc Committees 3 Final program 4 Life Achievement Award 4 Program at a glance 5 Wednesday, December 4 6 Thursday, December 5 8 Friday, December 6 12 Saturday, December 7 16 Posters presentation 19 Theme 1: Clinical trials: Methodology 20 Theme 2: Clinical trials: Results 23 Theme 3: Clinical trials: Imaging 24 Theme 4: Clinical trials: Biomarkers including plasma 26 Theme 5: Clinical trials: Cognitive and functional endpoints 29 Theme 6: Cognitive assessment and clinical trials 31 Theme 7: Behavioral disorders and clinical trials 33 Theme 8: Health economics and clinical trials 33 Theme 9: Epidemiology and clinical trials 33 Theme 10: Clinical Trials: Animals Models 34 Theme 11: New therapies and clinical trials 34 Privileged partners 37 CTAD 2019 General information 38 San Diego ©Terry Healy - Graphic designer: Kom Graphik ©Terry CTAD Organizing Committee Jacques Touchon MD, PhD University Hospital of Montpellier CTAD Scientific Committee France Susan ABUSHAKRA (San Francisco); Paul AISEN (San Diego); Kaj BLENNOW (Molndal); Merce BOADA Paul Aisen MD (Barcelona); Maria CARRILLO (Chicago); Mony John DE Alzheimer’s LEON (New York); Steven DEKOSKY (Gainesville); Rachelle Therapeutic Research Institute (ATRI) DOODY (Basel); Bruno DUBOIS (Paris); Howard FELDMAN University of Southern California (USC), (San Diego); Nick FOX (London); Giovanni B. FRISONI San Diego, USA (Brescia, Geneva); Lutz FROELICH (Mannheim); Serge GAUTHIER (Montreal); Ezio GIACOBINI (Geneva); Michael GRUNDMANN (San Diego); Harald HAMPEL (Woodcliff Bruno Vellas MD, PhD Lake); Takeshi IWATSUBO (Tokyo); Ara KHACHATURIAN University (Washington DC); Zaven KHACHATURIAN (Washington Hospital of Toulouse DC); Virginia LEE (Philadelphia); Constantine G. France LYKETSOS (Baltimore); José Luis MOLINUEVO (Barcelona); Jean-Marc ORGOGOZO (Bordeaux); Ronald PETERSEN Mike Weiner MD (Rochester); Craig W.
    [Show full text]
  • Whole-Genome Shotgun Assembly and Analysis of the Genome Of
    R ESEARCH A RTICLE of the human genome, it contains a comparable complement of protein-coding genes, as in- Whole-Genome Shotgun ferred from random genomic sampling (3). Subsequently, more-targeted analyses (5–9) Assembly and Analysis of the showed that the Fugu genome has remarkable homologies to the human sequence. The intron- Genome of Fugu rubripes exon structure of most genes is preserved be- tween Fugu and human, in some cases with Samuel Aparicio,2,1* Jarrod Chapman,3 Elia Stupka,1* conserved alternative splicing (10). The relative Nik Putnam,3 Jer-ming Chia,1 Paramvir Dehal,3 compactness of the Fugu genome is accounted Alan Christoffels,1 Sam Rash,3 Shawn Hoon,1 Arian Smit,4 for by the proportional reduction in the size of introns and intergenic regions, in part owing to Maarten D. Sollewijn Gelpke,3 Jared Roach,4 Tania Oh,1 3 1 3 1 the relative scarcity of repeated sequences like Isaac Y. Ho, Marie Wong, Chris Detter, Frans Verhoef, those that litter the human genome. Conserva- 3 1 3 3 Paul Predki, Alice Tay, Susan Lucas, Paul Richardson, tion of synteny was discovered between hu- Sarah F. Smith,5 Melody S. Clark,5 Yvonne J. K. Edwards,5 mans and Fugu (5, 6), suggesting the possibil- Norman Doggett,6 Andrey Zharkikh,7 Sean V. Tavtigian,7 ity of identifying chromosomal elements from Dmitry Pruss,7 Mary Barnstead,8 Cheryl Evans,8 Holly Baden,8 the common ancestor. Noncoding sequence 9 4 4 4 comparisons detected core conserved regulato- Justin Powell, Gustavo Glusman, Lee Rowen, Leroy Hood, Downloaded from ry elements in mice (11).
    [Show full text]
  • A Personal View of Molecular Technology and How It Has Changed Biology Leroy Hood President and Director, Institute for Systems Biology, Seattle, Washington 98103
    A Personal View of Molecular Technology and How It Has Changed Biology Leroy Hood President and Director, Institute for Systems Biology, Seattle, Washington 98103 Received June 27, 2002 I have had the pleasure of practicing biology and technology development for the past 35 yearssfirst at the National Institutes of Health (NIH) for 3 years, then at the California Institute of Technology (Caltech) for 22 years, subsequently at the University of Washington (UW) for 8 years, and finally at the Institute for Systems Biology (ISB) for the past 2 years. In each case, my geographical transitions were prompted by exciting new opportunities and evolving visions of how biology should be practiced. The technology developments I have been associated with over this period helped to catalyze two emerg- Figure 1. Quotes from Freeman J. Dyson, Imagined Worlds ing paradigm changes in biology: systems biology and predic- (Harvard University Press: Cambridge, MA, 1998). tive/preventive medicine. Table 1. Colleagues for Instrument and Strategy Development My career has been driven by two imperatives from my Ph.D. advisor, Bill Dreyer (Caltech). First, ªAlways practice biology Ruedi Aebersold protein blotting, protein microsequencing at the leading edge.º For much of my career, this leading edge Bruce Birren pulse-field gel electrophoresis Alan Blanchard ink-jet DNA synthesizer was molecular immunology.1-14 Second, ªWith new technolo- Ian Clark-Lewis long peptides gies, biologists have the chance to open up new horizons for Cecilie Boysen BAC shotgun sequencing exploration in biology.º Indeed, Freeman Dyson made this Pat Griffin mass spectrometry and proteins point eloquently (Figure 1).
    [Show full text]
  • 2015 Scientific Strategic Plan
    2014 - 2015 Scientific Strategic Plan Institute for Systems Biology VISION: Facilitate wellness, predict and prevent disease and enable environmental sustainability. STRATEGY: Develop a powerful approach to predict and engineer state transitions in biological systems. TACTICS: We will execute this strategy through four tactics: 1. Develop a theoretical framework to define states and state transitions in biological systems. 2. Use experimental systems to quantitatively characterize states and state transitions. 3. Invent technologies to measure and manipulate biological systems. 4. Invent computational methods to identify states and model dynamics of underlying networks. APPLICATIONS: We will drive tactics with applications to enable predictive, preventive, personalized, and participatory (P4) medicine and a sustainable environment. INTRODUCTION MISSION We will revolutionize science with a powerful systems approach to predict and prevent disease, and enable a sustainable environment. STRATEGY ISB will develop a systems approach to characterize, predict, and manipulate state transitions in biological systems. This strategy is the common denominator to accomplish the two vision goals. By studying similar phenomena across diverse biological systems (microbes to humans) we will leverage varying expertise, ideas, resources, and opportunities to develop a unified systems biology framework. 2 Learn more about our scientists at: systemsbiology.org/people INTRODUCTION ISB IS A UNIQUE ORGANIZATION ISB is neither a classical definition of an academic organization nor is it a biotechnology company. We are unique. Unlike in traditional academic departments, our faculty are cross-disciplinary and work collaboratively toward a common vision. This cross-disciplinary approach enables us to take on big, complex problems. While we are vision-driven, ISB is also deeply committed to transferring knowledge to society.
    [Show full text]
  • DR. LEROY E. HOOD Curriculum Vitae Business Address: Institute For
    DR. LEROY E. HOOD Curriculum Vitae Business Address: Institute for Systems Biology 401 Terry Avenue North Seattle, Washington 98109 Phone: (206) 732-1201 Fax: (206) 732-1260 www.systemsbiology.org E-mail: [email protected] Date and Place of Birth: Missoula, Montana - October 10, 1938 Citizenship: United States Marital Status: Married 1963, two children Education: 1960 - B.S. California Institute of Technology (Biology) 1964 - M.D. The Johns Hopkins School of Medicine (Medicine) 1968 - Ph.D. California Institute of Technology (Biochemistry) - Immunoglobulins: Structure, Genetics, and Evolution Research Interests: Systems biology and medicine Genomics Technology development Personalized medicine cancer Neurodegeneration Clinical assays Non-Scientific Interests: Mountaineering and climbing Photography Running Science fiction Professional Experience: 1963-1964 NIH Predoctoral Fellowship, California Institute of Technology 1964-1967 NIH Postdoctoral Fellowship, California Institute of Technology 1967-1970 Senior Investigator, Immunology Branch, GL&C, NCI, National Institutes of Health, Bethesda, MD 1970-1973 Assistant Professor of Biology, California Institute of Technology 1973-1975 Associate Professor of Biology, California Institute of Technology 1975-1977 Professor of Biology, California Institute of Technology 1977-1992 Bowles Professor of Biology, California Institute of Technology 1980-1989 Chairman, Division of Biology, California Institute of Technology 1981-1990 Director, Cancer Center, California Institute of Technology 1989-1992
    [Show full text]
  • Poster Session I, December 4, 2017
    Neuropsychopharmacology (2017) 42, S111–S293 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org Poster Session I Methods: We recruited a sample of (N = 63) African- Palm Springs, California, December 3-7, 2017 American women with T2DM and high rates of lifetime trauma exposure from the primary care and diabetes Sponsorship Statement: Publication of this supplement is specialty clinic waiting rooms of Grady Memorial Hospital, sponsored by the ACNP. a large county hospital and level 1 trauma center in Atlanta, Individual contributor disclosures may be found within the Georgia. PTSD diagnosis and PTSD symptom severity were abstracts. Part 1: All Financial Involvement with a pharma- determined using the Clinician-Administered PTSD Scale ceutical or biotechnology company, a company providing (CAPS). A fasting blood sample was collected and a study clinical assessment, scientific, or medical products or compa- physician performed a general medical assessment for each nies doing business with or proposing to do business with participant. Blood was assayed for hemoglobin A1c (HbA1c) ACNP over past 2 years (Calendar Years 2014–Present); Part and calculation of average estimated glucose (AEG) con- 2: Income Sources & Equity of $10,000 per year or greater centrations. Peripheral blood mononuclear cells (PBMCs) (Calendar Years 2014 - Present): List those financial relation- were extracted and assayed for nuclear factor-κB (NF-κB) ships which are listed in part one and have a value greater than pathway activity and monocyte glucocorticoid sensitivity $10,000 per year, OR financial holdings that are listed in part (expressed as dexamethasone [DexIC50]) using previously one and have a value of $10,000 or greater as of the date of validated methods.
    [Show full text]
  • 21St Century Medicine: Big Data, Wellness, Disease
    21st Century Medicine: Big Data, Wellness, Disease Lee Hood, MD, PhD Senior VP and Chief Strategy Officer Institute for Systems Biology, Seattle Measuring Man Senior VP and Chief Science Officer Providence St. Joseph Health, Seattle October 10, 2019 01 The grand challenge for biology and medicine: Deciphering biological complexity (1970, Assistant Professor Caltech) 08 I Participated in Seven Paradigm Changes in Biology Dealing with Complexity Which Led to My View of 21st Century Medicine Brought engineering The Human to biology Genome -1970 1 2 Project -1990 Cross-disciplinary 1970 biology 3 -1992 Systems biology— 2000-ISB 4 Luxembourg Scientific (quantitative) Wellness: deep, longitudinal, personal Bringing P4/21st century phenotyping—2014 medicine to the US Conceptualization Arivale 2015 healthcare system via of systems medicine 5 Providence St. and P4 healthcare Joseph Health 2000-2004 6 7 Present 09 Two Paradigm Changes in the Last 100 Years Framing US Medicine 1900s 2000s Systems medicine Germ Theory P4 healthcare Predict It Chemistry Find It Scientific wellness Prevent it Physiology Fix It Genomics Personalize It Pathology Deep phenotyping of Physics Participatory individuals N=1 (Omics) Precision medicine Digital self measurements Microbiomes st Understanding 20th Century Medicine Systems Approaches to Systems-Driven 21 Disease Understanding Wellness, Century Medicine Disease, and their Transitions 10 Institute for Systems Biology Non-profit scientific research organization founded in 2000 2019 • 12 faculty, 220 staff • $40 million
    [Show full text]
  • Poster Presentations
    POSTER PRESENTATIONS THEME 1: Clinical trials methodology P1: Underrepresented Elders in The Brain Health Registry: US Representativeness and Registry Behavior Miriam ASHFORD (1, 2), Joseph EICHENBAUM (1, 2, 3), Tirzah WILLIAMS (1, 2, 3), Juliet FOCKLER (2, 3), Monica CAMACHO (1, 2), Aaron ULBRICHT (2, 3), Derek FLENNIKEN (1, 2), Diana TRURAN (1, 2), R. Scott MACKIN (2, 4), Michael W. WEINER (1, 2, 3), Rachel L NOSHENY (2, 4) - (1)Northern California Institute for Research and Education (NCIRE), United States, (2)Department of Veterans Affairs Medical Center, Center for Imaging and Neurodegenerative Diseases, United States, (3)Department of Radiology and Biomedical Imaging, University of California, United States, (4)Department of Psychiatry, University of California San Francisco, United States P2: A Phase 3- Efficacy and Safety Study Protocol of Traneurocin (NA-831) in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia (PREVENTION) Lloyd TRAN, Fern VU, Stephanie NEAVE, Brian TRAN - (1)NeuroActiva, Inc., United States P3: Using Network Analysis and Machine Learning Methods to Evaluate the Efficacy of Lemborexant in Patients with Irregular Sleep Wake Rhythm Disorder and Alzheimer’s Disease Dementia Margaret MOLINE, Nusrat RABBEE - (1)Eisai, Inc., United States P4: Medicare Advantage – Impact of New Memory Fitness Benefit and Reimbursement Structure to Increase Referrals to Alzheimer’s Disease Clinical Trials John DWYER, Cyndy CORDELL - (1)The Global Alzheimer’s Platform (GAP) Foundation, United States P5: Suitability
    [Show full text]
  • Institute for Systems Biology Annual Report 2010
    Institute for Systems Biology Annual Report 2010 ///////////////////////////////////////////////////////////////////////////////////////////////////// ///////////////////////////////////////////////////////////////////////////////////////////////////// T.O.C. p2 REPORT FROM THE CHAIRMAN & CO-FOUNDER AND PRESIDENT OF ISB //////////////////////////////////////////////////////////////////////////////////////////////////////////// p5 p6 p7 p8 HUMAN THE CANCER SYSTEMS ENVIRONMENTAL PROTEOME GENOME GENETICS SUSTAINABILITY PROJECT ATLAS p10 STRATEGIC PARTNERSHIPS p11 P4 MEDICINE INSTITUTE p13 CENTER FOR INQUIRY SCIENCE p14 GOVERNANCE AND LEADERSHIP p16 FINANCIAL HIGHLIGHTS p19 2010 ISB PUBLICATIONS Photography by Robin Layton unless otherwise noted REPORT FROM THE CHAIRMAN & CO-FOUNDER AND PRESIDENT ////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// As we formally celebrated the Institute for Sys- tems Biology’s (ISB’s) 10th Anniversary, we had a wonderful year with outstanding science. As we refl ect on our fi rst decade at ISB – building a remarkable track record of achievement and cre- Leroy Hood, MD, PhD ativity – and this year’s accomplishments, we want Co-founder and President to also provide you with a snapshot of our vision for the future. Pushing Boundaries ISB’s Mission and Areas of Focus: Complexity
    [Show full text]